Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2026)

Alx Oncology Holdings has reported Capital Expenditures for 8 years, with the latest figure at $50000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 16.67% year-over-year to $50000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202000.0 (down 43.73% YoY) and the FY2025 annual result came in at $212000.0, down 52.57% from the prior year.
• Capital Expenditures climbed to $50000.0 in Q1 2026 per ALXO's latest filing, from $49000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.7 million in Q2 2023 and troughed at -$1.3 million in Q3 2023.
• A 5-year average of $200588.2 and a median of $90000.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 8314.29% in 2022, then plunged 4443.33% in 2023.
• Over 5 years, Capital Expenditures stood at $551000.0 in 2022, then sank by 73.14% to $148000.0 in 2023, then tumbled by 59.46% to $60000.0 in 2024, then fell by 18.33% to $49000.0 in 2025, then climbed by 2.04% to $50000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $50000.0, $49000.0, and $56000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.